#Mexico #Mexico City #Bracco Imaging #VUEWAY #gadopiclenol

Bracco Imaging Expands MRI Capabilities in Mexico with VUEWAY® Injection

Bracco Imaging, a renowned name in diagnostic imaging, is making waves in healthcare by announcing the commercial launch of its innovative contrast agent, VUEWAY® injection (gadopiclenol), in Mexico. Approved by the Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) in September 2025, this cutting-edge agent is now readily accessible for use in contrast-enhanced magnetic resonance imaging (CE-MRI) for both adults and children aged two years and older.

This significant approval is not just a triumph for Bracco but a step towards safer imaging practices globally, reflecting the company’s commitment to providing lower-dose MRI solutions across various markets. VUEWAY® has been shown to deliver effective contrast enhancement while reducing patient exposure to gadolinium, adhering to clinical recommendations that advocate for the minimal effective dosage in imaging procedures.

According to Tommaso Montemurno, the General Manager for Latin America at Bracco Imaging, the introduction of VUEWAY® injection in Mexico is a major milestone that emphasizes their strategic growth in Latin America. He stated, "This innovative contrast agent expands access to advanced MRI imaging in Mexico, supporting high-quality diagnostic performance and addressing the evolving needs of clinical practice." This product not only fortifies Bracco's MRI portfolio but also broadens healthcare professionals' options, ensuring a higher standard of imaging services across the region.

Hector Sanchez, the Commercial Director for Mexico at Bracco Imaging, echoed these sentiments by highlighting the role of VUEWAY® injection as a next-generation contrast agent. Sanchez emphasized, "The launch of VUEWAY® injection marks a pivotal moment in enhancing innovation in diagnostic imaging. As a next-generation contrast agent, VUEWAY® offers a unique profile that empowers healthcare providers to execute high-quality imaging with confidence, while prioritizing patient safety."

The approval from COFEPRIS is part of Bracco's global effort, as VUEWAY® injection has achieved regulatory milestones in numerous countries, including the European Union and the United States, where it is now approved in 38 nations. Over 4 million doses of VUEWAY® have been administered worldwide, and the approved indications in regions like the EU and the US have extended to include neonates and infants, showcasing the agent's versatility and safety across diverse patient populations.

About Gadopiclenol

Gadopiclenol, the core component of VUEWAY®, represents a new era of gadolinium-based contrast agents (GBCAs) distinguished by its high relaxivity. Initially developed by Guerbet, with significant contributions from Bracco, the product's efficacy and safety have been validated through rigorous evaluations across multiple medical imaging sectors, including examinations of the central nervous system, head and neck, thorax, abdomen, pelvis, and musculoskeletal system. Notably, the product has gained approval for pediatric use from birth, both by the FDA in the US and the EMA in Europe, reinforcing its profile as a safe and effective imaging solution.

Details regarding the phase III clinical trials that explored gadopiclenol's efficacy and safety are also accessible for further subdivisions of the medical community interested in the science behind this innovative formula.

Strategic Collaboration

In December 2021, Bracco Imaging and Guerbet initiated a worldwide collaboration focusing on the manufacturing and research development of gadopiclenol, with both companies maintaining separate commercialization pathways. This partnership aims to expedite patient access to gadopiclenol, propelling innovation and enhancing care quality for patients and clinicians alike.

About Bracco Group

Established in 1927, the Bracco Group is a global leader in diagnostic imaging, focusing on advancing healthcare and improving lives through innovative solutions in prevention and precision medicine. Operating in over 100 countries with a workforce exceeding 4,000 and annual revenues around €2 billion, Bracco continues to invest approximately 9% of its turnover into research and development. This commitment underscores its dedication to creating a wide range of pharmaceutical products for diagnostic imaging, including contrast agents for X-ray, CT, MRI, and even microbubbles for enhanced ultrasound imaging. Bracco stands out as a market leader in advanced imaging technologies, positioning itself at the forefront of the medical imaging field. For further detail, visit www.bracco.com.

VUEWAY is a registered trademark of Bracco Imaging S.p.A. All other trademarks are the property of their respective owners. ©2026 Bracco Diagnostics Inc. All Rights Reserved.